Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion
AssigneeBlueprint Medicines Corporation
InventorsNicolas Stransky, Joseph L. Kim
Life of this patent
Estimating the term…
Abstract
The invention provides to PKN1 gene fusions, PKN1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PKN1 fusions, such as conditions mediated by aberrant PKN1 expression or activity, or over expression of PKN1.
Claims5
A method for detecting in a patient a Protein Kinase N1 (PKN1) fusion that results in aberrant activity or expression of PKN1 or overexpression of PKN1, wherein the PKN1 fusion is a Trans-2,3-enoyl-CoA reductase (TECR):PKN1 or Annexin A4 (ANXA4):PKN1 fusion, said method comprising:
- a) contacting a biological sample obtained from the patient with an oligonucleotide that hybridizes to the fusion junction of a PKN1 gene fusion;
- and
- b) detecting binding between the PKN1 gene fusion and the oligonucleotide.
Dependencies are inferred from the claim text.